NEW HAVEN, Conn., May 4, 2017 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced
the pricing of its initial public offering of 9,900,000 of its
common shares at an initial public offering price of $17.00 per share. In addition, Biohaven has
granted the underwriters a 30-day option to purchase up to an
additional 1,485,000 common shares at the initial public offering
price, less underwriting discounts and commissions. The
shares are expected to begin trading on the New York Stock Exchange
on May 4, 2017 under the ticker
symbol "BHVN."
The offering is expected to close on May
9, 2017, subject to customary closing conditions.
Morgan Stanley, Piper Jaffray
& Co. and Barclays Capital Inc. are acting as joint
book-running managers for the proposed offering. William Blair & Company, L.L.C. is acting as
lead manager. Needham & Company, LLC is acting as
co-manager.
The offering will be made only by means of a prospectus.
When available, copies of the final prospectus related to the
offering may be obtained from the offices of Morgan Stanley &
Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, New York 10014;
or from Piper Jaffray & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, or by
telephone at (800) 747-3924, or by email at prospectus@pjc.com; or
from Barclays Capital Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood,
NY 11717, telephone: (888) 603-5847, e-mail:
Barclaysprospectus@broadridge.com.
A registration statement relating to these securities has been
filed with, and declared effective by, the Securities and Exchange
Commission (the "SEC"). Copies of the registration statement can be
accessed through the SEC's website at www.sec.gov. This press
release shall not constitute an offer to sell, or the solicitation
of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a
portfolio of innovative, late-stage product candidates targeting
neurological diseases, including rare disorders. Biohaven has
licensed intellectual property from companies and institutions
including Bristol-Myers Squibb Company, AstraZeneca AB,
Yale University, Catalent, ALS
Biopharma LLC and Massachusetts General Hospital. Biohaven is
a company organized under the laws of the British Virgin Islands and its United States operations are based in
New Haven, Connecticut.
Contact
Dr. Vlad Coric
Chief Executive Officer
Biohaven Pharmaceutical Holding Company Ltd.
Phone: (203) 404-0410
Email: vlad.coric@biohavenpharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biohaven-announces-pricing-of-initial-public-offering-of-common-shares-300451520.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.